Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater

被引：0
|
作者：
Tambo, Yuichi [1 ]
Sone, Takashi [1 ]
Shibata, Kazuhiko [2 ]
Nishi, Kouichi [3 ]
Shirasaki, Hiroki [4 ]
Yoneda, Taro [5 ]
Araya, Tomoyuki [6 ]
Kase, Kazumasa [7 ]
Nishikawa, Shingo [1 ]
Kimura, Hideharu [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[2] Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan
[3] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
[4] Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Japan
[5] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Japan
[6] Natl Hosp Org Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan
[7] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO25-3
引用
收藏
页码：S313 / S313
页数：1
相关论文
共 50 条
  • [31] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [32] Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024
    Brahmer, Julie R.
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Deitz, Anne C.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Rangwala, Reshma
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S8 - S9
  • [33] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [34] Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
    Kobayashi, M.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Nagano, Y.
    Nakamura, A.
    Aso, M.
    Kimura, N.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Fujita, Y.
    Oizumi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1017 - S1017
  • [35] Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
    Marmarelis, M. E.
    Cantor, D. J.
    Mathew, D.
    McWilliams, T.
    Bauml, J.
    Hwang, W-T
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A.
    Wherry, J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S20 - S20
  • [36] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%
    Brahmer, J.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Riccio, A.
    Yang, J.
    Pietanza, M. C.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1793 - S1794
  • [37] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
    Awad, M. M.
    Gadgeel, S. M.
    Borghaei, H.
    Patnaik, A.
    Yang, J. Chih-Hsin
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Altan, M.
    Jalal, S. I.
    Panwalkar, A.
    Gubens, M.
    Sequist, L. V.
    Saraf, S.
    Zhao, B.
    Piperdi, B.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S8
  • [38] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    CANCERS, 2020, 12 (12) : 1 - 15
  • [39] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)
    Kitamura, Yasuo
    Mizugaki, Hidenori
    Ikezawa, Yasuyuki
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Oizumi, Satoshi
    ANNALS OF ONCOLOGY, 2022, 33 : S524 - S524
  • [40] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
    Nakamura, A.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Kitamura, Y.
    Morita, M.
    Aso, M.
    Tsukita, Y.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Nakamura, K.
    Yokouchi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1008
12345